Uno studio mascherato, controllato con placebo per valutare l'iptacopan nella degenerazione maculare senile
Uno studio randomizzato, partecipante e sperimentatore mascherato, controllato con placebo, multicentrico, proof-of-concept per valutare la sicurezza e l'efficacia di LNP023 (Iptacopan) in pazienti con degenerazione maculare correlata all'età precoce e intermedia
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).
Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:
- Iptacopan (LNP023) oral capsules
- Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Shanghai, Cina, 200080
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, Cina, 150001
- Novartis Investigative Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Cina, 300020
- Novartis Investigative Site
-
-
-
-
-
Arecibo, Porto Rico, 00612
- Emanuelli Research and Development Center LLC
-
-
-
-
-
London, Regno Unito, SE5 9RS
- Novartis Investigative Site
-
Southampton, Regno Unito, SO16 6YD
- Novartis Investigative Site
-
-
-
-
California
-
Fullerton, California, Stati Uniti, 92835
- Retina Consultants of Orange County
-
Huntington Beach, California, Stati Uniti, 92647
- Salehi Retina Institute
-
Rancho Cordova, California, Stati Uniti, 95670
- Martel Eye Medical Group
-
Sacramento, California, Stati Uniti, 95841
- Retinal Consultants Medical Group Inc
-
Santa Barbara, California, Stati Uniti, 93103
- California Retina Consultants
-
-
Colorado
-
Durango, Colorado, Stati Uniti, 81303
- Southwest Retina Research Center
-
-
Florida
-
Deerfield Beach, Florida, Stati Uniti, 33064
- Advanced Research LLC
-
Delray Beach, Florida, Stati Uniti, 33484
- Retina Center Of South Florida
-
St. Petersburg, Florida, Stati Uniti, 33711
- Retina Vitreous Associates of Florida
-
-
Indiana
-
Carmel, Indiana, Stati Uniti, 46032
- Midwest Eye Institute
-
-
Louisiana
-
Metairie, Louisiana, Stati Uniti, 70001
- Retina Associates New Orleans
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21209
- Retina Care Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Opthamalic Consultants of Boston
-
-
New Jersey
-
Bloomfield, New Jersey, Stati Uniti, 07003
- Envision Ocular LLC
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27705
- Duke Eye Center
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97210
- Retina Northwest PC
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti, 38138
- Charles Retina Institute
-
-
Texas
-
Austin, Texas, Stati Uniti, 78793
- Austin Research Center for Retina
-
Bellaire, Texas, Stati Uniti, 77401
- Retina Consultants TX Rsrch Ctr
-
Dallas, Texas, Stati Uniti, 75231
- Retina Foundation
-
Fort Worth, Texas, Stati Uniti, 76104
- Texas Retina Associates
-
Houston, Texas, Stati Uniti, 77030
- Retina Consultants of Houston PA
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female participants ≥ 50 years of age
- Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
- Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
- Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
- Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
- If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.
Exclusion Criteria:
- History or current diagnosis of ECG abnormalities indicating significant safety risk, such as clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
- History of familial long QT syndrome or known family history of Torsades de Pointes
- History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
- History of end stage kidney disease requiring dialysis or renal transplant
- History of malignancy of any organ system
- History of solid organ or bone marrow transplantation
- History of recurrent meningitis or history of meningococcal infections despite vaccination
- History of immunodeficiency diseases, including a positive Human Immunodeficiency Virus test result at Screening
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
- Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
- Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Iptacopan (LNP023)
Iptacopan (LNP023) oral use capsules |
oral capsules |
|
Comparatore placebo: Placebo
Placebo matched to study drug, oral use capsules |
oral capsules |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging
Lasso di tempo: Baseline/Day 1 through Month 24
|
OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines |
Baseline/Day 1 through Month 24
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The incidence of ocular and non-ocular adverse events (AEs)
Lasso di tempo: Baseline/Day 1 through Month 24
|
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. |
Baseline/Day 1 through Month 24
|
|
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye
Lasso di tempo: Baseline/Day 1 through Month 24
|
Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye
Lasso di tempo: Baseline/Day 1 through Month 24
|
ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye
Lasso di tempo: Baseline/Day 1 through Month 24
|
Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read. |
Baseline/Day 1 through Month 24
|
|
Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye
Lasso di tempo: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
|
Pharmacokinetics - concentrations of LNP023 related to trough samples
Lasso di tempo: Baseline/Day 1 through Month 24
|
Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method. |
Baseline/Day 1 through Month 24
|
|
Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye
Lasso di tempo: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del sistema nervoso
- Malattie degli occhi
- Disturbi della sensibilità
- Malattie retiniche
- Degenerazione retinica
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Degenerazione maculare
- Atrofia geografica
- Degenerazione maculare umida
- Disturbi della vista
- iptacopan
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CLNP023E12201
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .